Powerful and Established Efficacy1-3 Add Once-daily Oxtellar XR® for Partial Seizures

Learn More

These images are fictionalized for illustrative purposes only.

Commercially Insured Patients May Qualify for $0 Co-pay for 12 months* Add Once-daily Oxtellar XR® for Partial Seizures

Learn More

These images are fictionalized for illustrative purposes only.

Commitment to Patient and Physician Support and Services Add Once-Daily Oxtellar XR® for Partial Seizures

Learn More

These images are fictionalized for illustrative purposes only.

References

  1. Data on file. Supernus Pharmaceuticals, Inc., Rockville, MD.
  2. French JA, Baroldi P, Brittain ST, Johnson JK; on behalf of the PROSPER Investigators Study Group. Efficacy and safety of extended-release oxcarbazepine (Oxtellar XR™) as adjunctive therapy in patients with refractory partial-onset seizures: a randomized controlled trial. Acta Neurol Scand. 2014;129:143-153.
  3. Oxtellar XR [package insert]. Rockville, MD: Supernus Pharmaceuticals, Inc.; December 2015.
Top